A recent systematic review of the literature reported on randomized controlled trials and nonrandomized studies on the use of granulocyte colony-stimulating factor therapies (G-CSFs) to reduce the incidence of febrile neutropenia, and found that short- and long-acting therapies, when dosed according to guidelines, have little difference in their efficacy.
Given that chemotherapy-induced neutropenia is one of the most frequent adverse events (AEs) associated with cytotoxic chemotherapy and often leads to febrile neutropenia (FN), effective prophylaxis with granulocyte colony-stimulating factor therapies (G-CSFs) is key. A recent systematic review of the literature reported on randomized controlled trials (RCTs) and nonrandomized studies on the use of G-CSFs to reduce the incidence of FN, and found that short- and long-acting therapies, when dosed according to guidelines, have little difference in their efficacy.
Publications eligible for inclusion in the review involved adults with nonmyeloid malignancies receiving chemotherapy. The literature search resulted in 45 eligible references. Seventeen publications reported on RCTs and 28 reported on other studies; 22 studies compared the short-acting filgrastim with the long-acting pegfilgrastim, 1 study used sargramostim as concomitant therapy, and 4 studies compared filgrastim or the short-acting lenograstim with pegfilgrastim, while 2 studies compared biosimilar filgrastim with filgrastim and pegfilgrastim.
None of the RCTs found a statistically significant difference in the incidence of FN between short- and long-acting G-CSFs. Among non-RCTs, 6 publications noted no significant difference between short- and long-acting G-CSFs, while 5 reported that pegfilgrastim was superior to filgrastim. One non-RTC reported a numerical trend toward the superiority of pegfilgrastim, but did not provide a statistical analysis. One non-RTC reported that filgrastim was more effective than pegfilgrastim.
Use of a fixed-effect model on RCTs demonstrated that although the risk of FN with long-acting G-CSFs was generally lower than with short-acting agents, the risk difference was not statistically significant. A sensitivity analysis confirmed this finding, and an analysis of non-RTCs found that the overall effect of long-acting G-CSF on FN was almost the same as that of short-acting G-CSF.
All RTCs showed similar levels of dose reduction of chemotherapy or delays in anticancer treatment for short- and long-acting agents. Three RCTs showed no significant difference in treatments in terms of hospitalization outcomes among treatments, while 2 reported a trend toward fewer hospitalizations with pegfilgrastim.
“Overall, the weight of evidence indicates little difference in efficacy between the short- and long-acting drugs if the short-acting G-CSF is dosed according to recommended guidelines,” wrote the authors.
Reference
Cornes P, Gascon P, Chan S, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther. 2018;35(11): 1816-1829. doi: 10.1007/s12325-018-0798-6.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.